Ποια είναι η τιμή για Energenesis Biomedical CO.,LTD. (6657)

Η τιμή για Energenesis Biomedical CO.,LTD. (6657) είναι $0.97305026

Ποια είναι η κεφαλαιοποίηση αγοράς για Energenesis Biomedical CO.,LTD. (6657)

Η κεφαλαιοποίηση αγοράς για Energenesis Biomedical CO.,LTD. (6657) είναι $85.54M

Energenesis Biomedical CO.,LTD. (6657) Τιμή και Κεφαλαιοποίηση Αγοράς

Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses: ENERGI-F711, formulated as a cream for burns. ENERGI-F702, designed to combat metabolic diseases. ENERGI-F704, targeting inflammatory bowel disease. ENERGI-F708, for the management of asthma. ENERGI-F705, aimed at controlling Parkinson's disease. ENERGI-F707, addressing mitochondrial deficiencies. ENERGI-F706, used to treat cachexia. ENERGI-F709, which serves as a vaccine adjuvant. ENERGI-F710, intended for the regulation of blood phosphate levels. Beyond its therapeutic developments, Energenesis Biomedical also provides a selection of scientific research products, including reagents for Western blotting, cell culture supplements, components for protein isolation and quantification, various laboratory dyes, and buffer solutions.

Η τιμή για 6657	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$59,282.32 $85.54M	NVDA	$5.211T	+6,092,321.50%
$51,721.85 $85.54M	AAPL	$4.547T	+5,315,335.08%
$47,350.56 $85.54M	GOOG	$4.162T	+4,866,098.99%
$40,870.06 $85.54M	MSFT	$3.593T	+4,200,100.74%
$31,770.33 $85.54M	AMZN	$2.793T	+3,264,924.23%

Η τιμή για 6657

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$59,282.32 $85.54M